Moleculin Biotech reported second quarter 2026 financial results and highlighted positive interim data from its pivotal MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia. Complete remission rates were at least three times higher than the control arm, with 43% and 36% observed in the two treatment cohorts versus 12% for control. The company raised $9.3 million in financing proceeds after the quarter end, bringing total cash resources to approximately $16.6 million alongside existing balances, which is expected to fund operations into the first quarter of 2027. R&D expenses increased to $5.5 million from $3.6 million in the prior year period due to clinical trial costs. The company operates as a clinical-stage pharmaceutical developer focused on oncology therapies.

Moleculin Biotech, Inc. completed a public offering of common stock and warrants on August 3, 2026, raising approximately $9.3 million in gross proceeds. The company issued 12,376,667 shares (or pre-funded warrants) alongside Series I Common Stock Purchase Warrants for up to 37,130,001 additional shares at a combined price of $0.75 per unit. Roth Capital Partners served as placement agent with a 6.5% fee, while Maxim Group acted as financial advisor for a 1.0% fee. Proceeds will fund clinical development of Annamycin and working capital needs. The company agreed to a 45-day lock-up on new issuances and an 180-day restriction on variable rate transactions. Moleculin Biotech operates in the biotechnology industry, focusing on drug discovery and development.

Moleculin Biotech announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in combination with cytarabine to treat relapsed or refractory acute myeloid leukemia. Among 62 evaluable subjects, the complete remission rate was 24% and composite complete remission rate was 37%. These rates remained consistent among the 30 patients who had previously failed venetoclax-based therapy. Enrollment has reached 74 of 90 planned subjects, with final Part A treatment expected in September 2026 and comprehensive unblinded results anticipated between December 2026 and February 2027. The company reported no evidence of cardiotoxicity. Moleculin Biotech is a clinical-stage pharmaceutical company developing therapeutic candidates for hard-to-treat tumors, including Annamycin for acute myeloid leukemia.

Moleculin Biotech, Inc. announced positive preliminary unblinded efficacy results from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial. The Annamycin treatment arms showed favorable efficacy trends compared to the control arm in patients with relapsed or refractory acute myeloid leukemia (R/R AML). Moleculin Biotech, Inc. is a biotechnology company focused on developing therapeutic solutions for hematologic malignancies.